Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Proteon Therapeutics (PRTO) PT Lowered to $1 at Baird
March 28, 2019 11:19 AM EDTBaird analyst Michael Ulz lowered the price target on Proteon Therapeutics (NASDAQ: PRTO) to $1.00 (from $3.00) while maintaining a Neutral rating.
Ulz commented, "This morning, Proteon announced disappointing top-line results from the Phase 3 PATENCY-2 study of vonapanitase, indicating the co-primary endpoints of fistula use for... More
Maxim Group Downgrades Proteon Therapeutics (PRTO) to Hold
March 28, 2019 10:42 AM EDTMaxim Group analyst Jason McCarthy downgraded Proteon Therapeutics (NASDAQ: PRTO) from Buy to Hold after second phase 3 study of vonapanitase failed to reach statistical significance on both co-primary endpoints.
For an analyst ratings summary and ratings history on Proteon Therapeutics... More
Proteon Therapeutics (PRTO) to Resume Trading at 8:30 am ET
March 28, 2019 8:08 AM EDTProteon Therapeutics (NASDAQ: PRTO) to Resume Trading at 8:30 am ET
